CD19 CAR T Cell Treatment for Children With Relapsed Leukemia or Lymphoma
Tests CD19-targeted CAR T cells in children with relapsed or resistant B-cell leukemia or lymphoma.
Plain-language title generated from the registry record
Registry title: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Key facts
- Where
- Tianjin, ChinaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 18 years old?
Source: NCT06355739, who can take part
Where in China
- Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical SciencesTianjin, ChinaTaking people
- InstituteHBDHTianjin, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhu Xiaofan
- Trial code
- NCT06355739
- Record updated
- 9 April 2024
- Original description
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in childrenRead full original descriptionShow less
Phase II Clinical Study on the Safety and Efficacy of Autotransfusion Agents Targeting CD19 Chimeric Antigen Receptor T Lymphocytes (BIC-19GG, BIC-2019,BIC-2219)in the Treatment of CD19-positive Children With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
Inclusion: 1, age 3-18 years old (including boundary value), male and female; The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoblastic; Patients with tumors who meet one of the following conditions:; Complete marrow response (MRD>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy; Complete response at the molecular level and immunology (characterized by specific molecular markers and immunophenotypes prior to treatment); Patients, did not turn negative after treatment); Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥; 12 months) and did not achieve complete remission after 1 course of standard induction regimen (MRD>1%); Recurrence after bone marrow transplantation; Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined; recrudescence; Lansky score ≥60; 4, the treatment related antigen test result is positive (CD19/CD20/CD22); The expected survival period from the signing date of the informed consent is more than 3 months; 6, HGB≥70g/L (blood transfusion); 7, liver and kidney function, cardiopulmonary function meet the following requirements:; Creatinine ≤1.5×ULN; Left ventricular ejection fraction ≥50%; Blood oxygen saturation >90%; Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-.
Exclusion: 1, severe cardiac insufficiency, left ventricular ejection fraction <50%; 2, have a history of severe lung function impairment; Combined with other advanced malignant tumors; 4, combined with serious infection and can not be effectively controlled; 5, combined with serious autoimmune disease or congenital immune deficiency; 6, active hepatitis (hepatitis B virus deoxyribonucleic acid [HBVDNA] or hepatitis C virus ribonucleic acid [HCVRNA] positive); 7, human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection; Have a history of severe allergy to biological products (including antibiotics); Patients with allogeneic hematopoietic stem cell transplantation still had acute graft-versus-host response (GvHD) one month after immunosuppressant discontinuation; 10, the presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, as well as patients deemed unsuitable for participation in the study by the investigator.